Armata Pharmaceuticals issues going-concern warning in 2025 10-K
Armata Pharmaceuticals issues going-concern warning in 2025 10-K as Q4 EPS misses, revenue $1.1M beats estimates
- Non-GAAP Q4 EPS was $-3.42, down 1387% year over year and missing analyst expectations.
- Q4 revenue totaled $1.1M, down 11% year over year but above consensus estimates.
- Company reported fourth-quarter and full-year 2025 results concurrently with filing its latest Form 10-K.
- Extensions of Innoviva credit agreement maturities move all outstanding obligations to a new June 1, 2027 deadline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.